Topic
What GLP-1 medications are approved, and at what doses?
Every FDA-approved GLP-1 medication, dose by dose, explained straight from the official labels.
GLP-1 Drugs Ranked by Effectiveness: Weight and A1C ResultsTirzepatide ranks first on both scoreboards: -20.9% body weight in SURMOUNT-1 and a 2.30-point A1C drop that beat semaglutide head to head. Injectable semaglutide is second, the orforglipron pill third on weight, liraglutide fourth. Direct trials back the top spots; the heart-protection scoreboard reshuffles the order.How to Store an Ozempic Pen, Inject It, and Throw It Away SafelyUnused Wegovy pens stay in the fridge at 36 °F to 46 °F and can sit out at 46 °F to 86 °F for up to 28 days before the cap comes off. Ozempic storage limits are in section 16 of its prescribing information. Inject once weekly into the abdomen, thigh, or upper arm, and throw used pens in a sharps container.Imcivree (Setmelanotide) Explained: Who It's For and How It WorksImcivree (setmelanotide) is an MC4 receptor agonist for rare obesity caused by hypothalamic injury or specific genetic conditions — not for ordinary obesity. On March 19, 2026, the FDA expanded approval to acquired hypothalamic obesity, making it the first approved therapy for that condition.Is Trulicity Being Discontinued? What's Actually Changing in 2026No. Trulicity is still marketed under an active FDA license, and Lilly is publishing 2026 pricing and savings offers. What is changing: Medicare selected Trulicity for price negotiation on January 27, 2026, with any negotiated price taking effect January 1, 2028.List of GLP-1 Medications: Every FDA-Approved Drug in 2026Nine GLP-1 brands are FDA-approved and sold in the US in 2026: Wegovy, Zepbound, Foundayo, Saxenda, Ozempic, Rybelsus, Mounjaro, Trulicity and Victoza. Byetta and Bydureon BCise were discontinued in 2024, CagriSema is under review, and the US semaglutide compound patent expires December 5, 2031.Mounjaro FAQ: Approved Uses, Dosing, Cost, and RisksMounjaro (tirzepatide) is FDA-approved to improve blood sugar in adults and children 10+ with type 2 diabetes and to reduce major cardiovascular events in high-risk adults. The list price is $1,112.16 per monthly fill; LillyDirect self-pay starts at $499/month.Mounjaro vs Zepbound: Same Drug, Different Approved UsesMounjaro and Zepbound are both tirzepatide injections made by Eli Lilly, approved under separate FDA applications: Mounjaro for type 2 diabetes and cardiovascular risk, Zepbound for weight management and obstructive sleep apnea.Ozempic vs Mounjaro: Differences, Dosing, and Which Is Better for Type 2 DiabetesOzempic (semaglutide) and Mounjaro (tirzepatide) are both once-weekly type 2 diabetes injections, but they are different molecules from different makers. In SURPASS-2, tirzepatide beat injectable semaglutide on A1C and weight, while only Ozempic carries a chronic kidney disease indication.Ozempic vs Wegovy vs Rybelsus: What Actually DiffersOzempic, Wegovy and Rybelsus all contain semaglutide, but they differ in approved uses, doses, shot vs pill, and price. The reformulated Rybelsus tablets were renamed Ozempic tablets on January 30, 2026, and the Rybelsus name is being retired in the US as the Ozempic pill rolls out from May 4, 2026.Soliqua vs Xultophy: How the Two Insulin + GLP-1 Pens CompareSoliqua 100/33 combines insulin glargine with lixisenatide; Xultophy 100/3.6 combines insulin degludec with liraglutide. Both are once-daily pens for adults with type 2 diabetes, but Xultophy carries a thyroid-tumor boxed warning and caps at 50 units, while Soliqua caps at 60 units.Switching GLP-1 Medications: What the Labels and Guidelines SayNo dose-conversion chart between different GLP-1 molecules appears in the FDA labels reviewed here. In these labels, switching instructions appear only within the semaglutide family and before starting fixed-ratio insulin combos. Up to one-fourth of patients switch off their first GLP-1 after year one.Trulicity vs Ozempic: Which Works Better, Dosage, and CostTrulicity (dulaglutide) and Ozempic (semaglutide) are GLP-1 injections for type 2 diabetes, and the retrieved labeling lists no weight-loss use for either. Trulicity lists at $1,006.93 per month; the Ozempic pill self-pays at $149 to $299 per month.Wegovy Pill: What It Is, How Well It Works, and What It CostsThe FDA approved the Wegovy pill (oral semaglutide) on December 22, 2025, the first oral GLP-1 for obesity in the US. In OASIS 4, people lost about 17% of body weight at 64 weeks if all stayed on treatment (about 14% regardless of adherence) vs about 3% on placebo; self-pay starts at $149 per month.Wegovy vs Zepbound: Weight Loss, Cost, Devices and Side EffectsWegovy (semaglutide) and Zepbound (tirzepatide) are both weekly injections for weight loss. In the one head-to-head trial, Zepbound produced 20.2% average weight loss versus 13.7% for Wegovy, though that study was open-label. Approved uses, devices and self-pay costs differ.What Happened to Byetta and Bydureon? Both Brands DiscontinuedAstraZeneca discontinued Byetta on Oct. 25, 2024 and Bydureon BCise on Oct. 28, 2024. FDA approved a generic twice-daily exenatide injection on 11/19/2024, though it cautions that approved drugs are not always available on the approval date.Zepbound Doses List vs. Mounjaro: Every Pen and Vial StrengthZepbound and Mounjaro both come in six tirzepatide strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg. Each strength exists as a single-dose pen or vial (0.5 mL per dose) and as a multi-dose vial or KwikPen holding 2.4 mL, which is four weekly 0.6 mL doses.Zepbound FAQ: Doses, Weight Loss, Side Effects, Storage and CostZepbound (tirzepatide) is approved for weight loss and for moderate to severe sleep apnea in adults with obesity. In trials, people lost up to 20.9% of body weight at 15 mg over 72 weeks; self-pay prices start at $299 per month.Zepbound for Sleep Apnea: Approval, Dose, Trial Results, and CostThe FDA approved Zepbound (tirzepatide) on December 20, 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. One-year trials showed 25 to 29 fewer breathing disruptions per hour and 18% to 20% weight loss; the trials tested it with and without PAP therapy, not stopping PAP.Zepbound Vials: What They Cost on LillyDirect and How to OrderA Zepbound single-dose vial holds one weekly dose of tirzepatide and costs $299 to $449 per month through LillyDirect self-pay, depending on dose. The $449 price for higher doses requires refilling within 45 days, and needles and syringes are sold separately.